An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients

• Status: Completed
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Asia. The aim of this observational study is, under normal clinical practice conditions, to investigate the clinical safety and effectiveness in Chinese patients with type 2 diabetes who have never received anti-diabetic treatment before.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Repaglinide

Criteria

Inclusion Criteria:

• HbA1c more than 6.5%, no anti-diabetes treatment accepted before entering the study

Exclusion Criteria:

• Subjects who received any anti-diabetic treatment previously

• Known or suspected allergy to trial product(s) or related products.

• Subjects who previously enrolled in this study.

• Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods.